リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Effectiveness of lacosamide in children and young adults previously treated with other sodium channel blockers」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Effectiveness of lacosamide in children and young adults previously treated with other sodium channel blockers

鈴木, 健史 名古屋大学

2022.07.01

概要

Purpose: This multicenter study examined the effectiveness and tolerability of lacosamide (LCM) for children and young adults with epilepsy, particularly in patients who had previously been treated with othersodium channel blockers (SCBs) and the difference in effectiveness and tolerability when using other concomitant SCBs.

Methods: We retrospectively studied the clinical information of patients aged <30 years given LCM totreat epilepsy. The effectiveness and adverse events (AEs) of LCM and the other SCBs were investigated.Factors related to the effectiveness and AEs of LCM, such as the number of antiepileptic drugs (AEDs) triedbefore LCM and concomitantly used SCBs, were also studied.

Results: We enrolled 112 patients (median age = 11 years). One year after starting LCM, 29% of thepatients were seizure free, and 50% had a 50% seizure reduction. Of the patients, 17% experiencedAEs, the most common being somnolence. A 50% seizure reduction was observed for LCM in 30% ofpatients in whom other SCBs had not been effective. Lacosamide produced a 50% seizure reduction in35% of the patients taking one concomitant SCB. By contrast, no patients had 50% seizure reduction,and 33% developed AEs, when LCM was administered concomitantly with two SCBs.

Conclusions: Lacosamide was effective in 30% of children and young adults in whom other SCBs had notbeen effective. The effectiveness of LCM may differ from that of other SCBs, and it is worth trying inpatients with epilepsy resistant to other AEDs.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

[1] Beydoun A, D’Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9:33–42. https://doi.org/10.1586/ 14737175.9.1.33.

[2] Farkas V, Steinborn B, Flamini JR, Zhang Y, Yuen N, Borghs S, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology 2019;93:e1212–26. https://doi.org/10.1212/ WNL.0000000000008126.

[3] Halász P, Kälviäinen R, Mazurkiewicz-Beldzin´ ska M, Rosenow F, Doty P, Hebert D, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443–53. 10.1111/j.1528-1167.2008.01951.x.

[4] Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308–17. https://doi.org/10.1111/j.1528- 1167.2007.01188.x.

[5] Brodie MJ. Sodium channel blockers in the treatment of epilepsy. CNS Drugs 2017;31:527–34. https://doi.org/10.1007/s40263-017-0441-0.

[6] Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav 2015;52:119–27. https:// doi.org/10.1016/j.yebeh.2015.09.006.

[7] Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Krebsfänger K, Scharfenecker U, et al. Lacosamide: A review of preclinical properties. Blackwell Publishing Inc; 2007.

[8] Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2017;16:43–54. https://doi.org/10.1016/S1474-4422(16)30292-7.

[9] Runge U, Arnold S, Brandt C, Reinhardt F, Kühn F, Isensee K, et al. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study. Epilepsia 2015;56:1921–30. https:// doi.org/10.1111/epi.13224.

[10] Hmaimess G, Sabbagh S, Dirani M, Hotait M, Beydoun AA, Nasreddine W. Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East. Seizure 2020;79:75–9. https://doi.org/10.1016/j.seizure.2020.04.016.

[11] Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58:522–30. https://doi.org/10.1111/epi.13670.

[12] Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069–77. https://doi.org/10.1111/j.1528-1167.2009.02397.x.

[13] Fukuyama K, Ueda Y, Okada M. Effects of carbamazepine, lacosamide and zonisamide on gliotransmitter release associated with activated astroglial hemichannels. Pharmaceuticals 2020;13:1–22. https://doi.org/10.3390/ ph13060117.

[14] Ahn JY, Yan BC, Park JH, Ahn JH, Lee DH, Kim IH, et al. Novel antiepileptic drug lacosamide exerts neuroprotective effects by decreasing glial activation in the hippocampus of a gerbil model of ischemic stroke. Exp Ther Med 2015;10:2007–14. https://doi.org/10.3892/etm.2015.2794.

[15] Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. Trends Neurosci 2013;36:174–84. https://doi.org/10.1016/j.tins.2012.11.008.

[16] Sanz P, Garcia-Gimeno MA. Reactive glia inflammatory signaling pathways and epilepsy. Int J Mol Sci 2020;21:1–17. https://doi.org/10.3390/ ijms21114096.

[17] McGinnis E, Kessler SK. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort. Epilepsia 2016;57:1416–25. https://doi.org/10.1111/epi.13466.

[18] Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314–9.

[19] Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78:1548–54.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る